Advertisement
Singapore markets open in 5 hours 48 minutes

  • Straits Times Index

    3,404.47
    -6.34 (-0.19%)
     

  • S&P 500

    5,567.56
    +0.37 (+0.01%)
     

  • Dow

    39,335.50
    -40.37 (-0.10%)
     

  • Nasdaq

    18,379.58
    +26.82 (+0.15%)
     

  • Bitcoin USD

    56,312.67
    -787.70 (-1.38%)
     

  • CMC Crypto 200

    1,207.14
    +41.03 (+3.52%)
     

  • FTSE 100

    8,193.49
    -10.44 (-0.13%)
     

  • Gold

    2,364.10
    -33.60 (-1.40%)
     

  • Crude Oil

    82.12
    -1.04 (-1.25%)
     

  • 10-Yr Bond

    4.2720
    0.0000 (0.00%)
     

  • Nikkei

    40,780.70
    -131.67 (-0.32%)
     

  • Hang Seng

    17,524.06
    -275.55 (-1.55%)
     

  • FTSE Bursa Malaysia

    1,611.02
    -5.73 (-0.35%)
     

  • Jakarta Composite Index

    7,250.98
    -2.40 (-0.03%)
     

  • PSE Index

    6,529.43
    +36.68 (+0.56%)
     

Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures

Vandana Singh
·2-min read
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures

Novo Nordisk A/S (NYSE:NVO), the maker of the popular obesity drug Ozempic, has been reprimanded by the U.K.’s Prescription Medicines Code of Practice Authority (PMCPA) for failing to disclose fees and expenses paid to individuals and organizations in Britain of approximately 7.8 million pounds (around $10 million) between 2020 and 2022.

On Friday, the U.K. industry body PMCPA announced that the reprimand followed a voluntary submission by Novo Nordisk regarding these payments.

Also Read: Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs.

The PMCPA stated that the payments involved over 150 bodies, including fees and expenses to health professionals, donations, grants, sponsorships, and other payments to healthcare organizations.

ADVERTISEMENT

Reuters report added that Novo Nordisk explained that these payments were for legitimate activities but were incorrectly categorized in their finance systems due to human error.

The PMCPA also reported breaches of the Association of the British Pharmaceutical Industry’s (ABPI) code of practice by Novartis AG (NYSE:NVS) and Pfizer Inc (NYSE:PFE).

The agency noted that the breaches discredited and reduced confidence in the pharmaceutical industry.

In March 2023, Novo Nordisk was suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years due to serious ABPI Code of Practice breaches.

ABPI’s statement linked to a complaint alleging that Novo Nordisk sponsored courses on weight management on LinkedIn for health professionals without clarifying the company’s involvement.

Price Action: NVO shares are

Read Next:

Photo via Shutterstock

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.